Barclays Forecasts Strong Price Appreciation for Danaher (NYSE:DHR) Stock

Danaher (NYSE:DHR) had its price objective lifted by stock analysts at Barclays from $225.00 to $250.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the conglomerate’s stock. Barclays‘s price target points to a potential upside of 12.30% from the company’s current price.

DHR has been the topic of a number of other research reports. Guggenheim reaffirmed a “buy” rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, July 23rd. Finally, Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Stock Performance

NYSE DHR opened at $222.62 on Wednesday. The company’s 50 day moving average is $202.49 and its 200-day moving average is $198.02. Danaher has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a quick ratio of 1.22, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm has a market cap of $157.25 billion, a P/E ratio of 45.90, a price-to-earnings-growth ratio of 3.31 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher will post 7.63 earnings per share for the current year.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently made changes to their positions in DHR. GAMMA Investing LLC boosted its stake in shares of Danaher by 22.2% in the 1st quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate’s stock valued at $1,871,000 after purchasing an additional 1,660 shares in the last quarter. Pacific Capital Partners Ltd purchased a new stake in shares of Danaher in the 1st quarter valued at $7,175,000. Oppenheimer & Co. Inc. boosted its stake in shares of Danaher by 9.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 25,096 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 2,122 shares in the last quarter. Valmark Advisers Inc. boosted its stake in shares of Danaher by 3.4% in the 1st quarter. Valmark Advisers Inc. now owns 2,365 shares of the conglomerate’s stock valued at $485,000 after purchasing an additional 78 shares in the last quarter. Finally, GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.